Findings

What do systematic reviews say?

156 questions · 164 findings · 46 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 36 · 22%GRADE not reported 5 · 3%Very low 47 · 28.7%Low 49 · 29.9%Moderate 20 · 12.2%High 7 · 4.3%

Intervention not reported

Adverse events · adult patients with haematological malignancies

The review found no eligible studies for this question.

1 finding from 1 review

Meditation for adults with haematological malignancies 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human soluble thrombomodulin vs heparin

Adverse events · DIC

It is very uncertain whether recombinant human soluble thrombomodulin changes adverse events compared with heparin (very low certainty).

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
RR 0.88 [0.35, 2.2]
1 study · 231 participants
Very low

Tranexamic acid vs placebo

Adverse events · DIC

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Dermatan vs heparin

Adverse events · DIC

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Human activated protein C vs heparin

Adverse events · DIC

It is very uncertain whether human activated protein C changes adverse events compared with heparin (very low certainty).

1 finding from 1 review

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
RR 0.53 [0.05, 5.66]
1 study · 107 participants
Very low

Intervention not reported

Adverse events · individuals with HL

It is very uncertain whether the intervention changes adverse events (very low certainty).

1 finding from 1 review

Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma 2015 · Cochrane Headline outcomes only
RR 0.91 [0.54, 1.53]
1 study · 160 participants
Very low

Yoga in addition to standard care vs standard‐of‐care therapy

Adverse events · participants with haematological malignancies

The review found no eligible studies for this question.

1 finding from 1 review

Yoga in addition to standard care for patients with haematological malignancies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events · Adult patients with follicular lymphoma

1 finding from 1 review

High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 527 participants
Very low

Colchicine plus standard care vs placebo or usual care

Adverse events ( · individuals with moderate or severe COVID‐19

1 finding from 1 review

Colchicine for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Very low

Immunomodulatory drug maintenance therapy vs placebo/observation

All adverse events · people with chronic lymphocytic leukaemia

Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).

1 finding from 1 review

Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
Rate ratio 1.41 [1.28, 1.54]
3 studies · 458 participants
Moderate

Anti‐CD20 mAb maintenance therapy vs observation

All adverse events · people with chronic lymphocytic leukaemia

Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).

1 finding from 1 review

Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
Rate ratio 1.23 [1.03, 1.47]
6 studies · 1321 participants
Low

Thrombopoietin mimetics vs placebo

All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 1.01 [0.96, 1.07]
5 studies · 390 participants
Moderate

Intervention not reported

Any adverse events ( · people with relapsed or refractory DLBCL

1 finding from 1 review

Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 550 participants
Very low

G‐CSF vs placebo

Severe adverse events · newly diagnosed patients with myelodysplastic syndromes

The review found no eligible studies for this question.

1 finding from 1 review

Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Convalescent plasma vs standard plasma

Serious adverse events · individuals with moderate to severe disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes serious adverse events compared with standard plasma (very low certainty).

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.8 [0.55, 1.15]
3 studies · 327 participants
Very low

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Serious adverse events · outpatients withmild disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events compared with placebo or standard care alone (low certainty).

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.14 [0.66, 1.94]
1 study · 376 participants
Low

JAK inhibitors plus standard of care vs placebo or usual care

Serious adverse events · hospitalised people with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2901 participants
Moderate

Bamlanivimab/etesevimab vs placebo

Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Bamlanivimab/etesevimab showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.4 [0.45, 4.37]
1 study · 1035 participants
Low

Casirivimab/imdevimab vs placebo

Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found